Individualized treatment of opioid dependence with weekly and monthly Buvidal® was well-tolerated and effective, with a high (73.6%) patient retention across the 48-week study
83.4% of participants transferred from daily sublingual buprenorphine responded that Buvidal® was better than their previous treatment
PR Newswire
LUND, Sweden, June 4, 2019